Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registryHjalmar Flygt, Johan Richter, Fredrik Sandin et al.|British Journal of Haematology|2021Cited by 15
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register studyTorsten Dahlén, Leif Stenke, Hans Wadenvik et al.|American Journal of Hematology|2022Cited by 15
The impact of Covid-19 in patients with chronic myeloid leukemia—a nationwide population-based studyTorsten Dahlén, Fredrik Nyberg, Hjalmar Flygt et al.|Leukemia|2023Cited by 5